

Table 2. Kinase Inhibitors tested

Inhibitor	Primary Targets	Status
<b>ABL/KIT Inhibitors</b>		
Imatinib	ABL, KIT, PDGFR	FDA approved
VX-680	Aurora	Phase I
MLN-518	FLT3, KIT	Phase I
BMS-354825	ABL, SRC	Phase II
SU-11248	FLT3, KIT	Phase III
BIRB-796	p38	Phase III (discont.)
PD-180970	ABL, KIT	Research compound
<b>EGFR Inhibitors</b>		
Gefitinib	EGFR	FDA approved
Erlotinib	EGFR	FDA approved
EKB-569	EGFR, ERBB2	Phase II
CI-1033	EGFR subfamily	Phase II
ZD-6474	VEGFR2, EGFR	Phase II
PKI-166	EGFR	Phase II (discont.)
GW-572016	EGFR, ERBB2, ERBB4	Phase III
CL-387785	EGFR	Research compound
SU-11464	EGFR	Research compound

FDA, Food and Drug Administration